Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | -59.3% | n/a |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | n/a | n/a |
PEG | n/a | n/a |
Pr/Revenue | 3.9 | n/a |
Pr/Book | n/a |
Latest | F'cast | |
---|---|---|
Revenue | -16.2% | n/a |
PBT | n/a | n/a |
EPS | n/a | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Jun-19 | 73.72 | 4.29 | 0.55p | 25.5 | n/a | n/a | n/a | 0.0% |
30-Jun-20 | 78.20 | 8.07 | 1.11p | 12.6 | 0.1 | +102% | n/a | 0.0% |
30-Jun-21 | 84.33 | 3.66 | 0.45p | 55.6 | n/a | -60% | n/a | 0.0% |
30-Jun-22 | 72.77 | (12.66) | (2.14)p | n/a | n/a | n/a | n/a | 0.0% |
30-Jun-23 | 60.95 | (49.83) | (7.61)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Trading update for the year ended 30 June 2024 | 22-Jul-2024 | 07:01 | RNS |
Appointment of Nominated Adviser and Sole Broker | 22-Jul-2024 | 07:00 | RNS |
Launch of new Company Long Term Incentive Plan | 04-Jul-2024 | 14:22 | RNS |
Allergy drug firm hit by trials setback | 12-Jul-2007 | The Independent |
Need to Know: Global Business Briefing | 25-Mar-2006 | Times |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 4.80p |
Change Today | -0.22p |
% Change | -4.38 % |
52 Week High | 6.00 |
52 Week Low | 1.30 |
Volume | 619,350 |
Shares Issued | 4,766.44m |
Market Cap | £228.79m |
RiskGrade | 268 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
16:35 | 1,341 @ 4.80p |
16:35 | 1,341 @ 4.80p |
16:28 | 33,645 @ 4.80p |
16:26 | 10,000 @ 4.80p |
15:27 | 688 @ 4.60p |
You are here: research